Intravitreales Methotrexat zur Behandlung eines uveitisch bedingten zystoiden Makulaödems

Maaß, J.; Matthé, Egbert

doi:10.1007/s00347-017-0548-1

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intravitreal use of nbDMARDs and bDMARDs, such as methotrexate, infliximab and adalimumab, is just limited to anecdotal reports in the medical literature [ 21 – 24 ]. A warning in using them routinely has to be made due to the lack of consistent evidence of both their safety and efficacy.…”

Section: Intravitreal Therapymentioning

confidence: 99%

New pharmacotherapy options for noninfectious posterior uveitis

2021

View full text Add to dashboard Cite

Introduction Noninfectious inflammation of the posterior eye segment represents an important cause of visual impairment. It often affects relatively young people and causes a significant personal and social impact. Although steroids and nonbiologic- Disease-Modifying Antirheumatic Drugs (nbDMARDs) are effective both in acute and long- lasting diseases, however they are increasingly being replaced by biologic (DMARDs). bDMARD. This article therefore aims to identify recent advances in the therapy of noninfectious posterior segment uveitis. Methods A Medline-search was conducted using the terms: nbDMARD, bDMARD, posterior uveitis, intermediate uveitis, treatment, corticosteroid. In addition, clinical studies were included as registered at ClinicalTrials.gov. Results Currently two major lines of treatments can be identified: (1) the intraocular application of anti-inflammatory agents and (2) the introduction of new agents, e.g., (bDMARDs) and small-molecule-inhibitors. Whereas intravitreal treatments have the advantage to avoid systemic side effects, new systemic agents are progressively earning credit on the basis of their therapeutic effects. Conclusion Even when current treatment strategies are still hampered by the limited number of randomized controlled trials, promising progress and continuous efforts are seen.

show abstract

Section: Intravitreal Therapymentioning

confidence: 99%